DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analyst sentiment is moderately positive: Five analysts covering DiaMedica Therapeutics assign the stock a consensus “Moderate Buy” rating, with four buys and one sell. The average 12-month price target is $12.00, compared with a recent share price of $6.85.
• Institutional ownership has increased: Several hedge funds and institutional investors recently initiated or expanded positions, though institutions collectively own only 10.12% of the company.
• DiaMedica remains an unprofitable clinical-stage biotech: The company posted a quarterly loss of $0.19 per share, slightly better than estimates, and analysts expect a full-year loss of $0.84 per share. Its lead candidate, rinvecalin (DM199), is being developed for acute ischemic stroke and kidney diseases.

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) have been given an average rating of "Moderate Buy" by the five ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $12.00.

DMAC has been the subject of a number of research analyst reports. Wall Street Zen upgraded shares of DiaMedica Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday, June 6th. HC Wainwright reiterated a "buy" rating and issued a $12.00 target price on shares of DiaMedica Therapeutics in a research note on Tuesday, August 11th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of DiaMedica Therapeutics in a research report on Friday, July 17th.

Hedge Funds Weigh In On DiaMedica Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. AXQ Capital LP purchased a new stake in DiaMedica Therapeutics in the fourth quarter worth $96,000. AWM Investment Company Inc. purchased a new position in shares of DiaMedica Therapeutics during the 2nd quarter valued at $253,000. World Investment Advisors lifted its position in shares of DiaMedica Therapeutics by 7.7% during the 4th quarter. World Investment Advisors now owns 36,975 shares of the company's stock valued at $294,000 after buying an additional 2,650 shares during the last quarter. Bank of America Corp DE grew its stake in shares of DiaMedica Therapeutics by 62.5% during the 1st quarter. Bank of America Corp DE now owns 42,768 shares of the company's stock worth $290,000 after acquiring an additional 16,446 shares during the period. Finally, Renaissance Technologies LLC bought a new position in shares of DiaMedica Therapeutics during the 1st quarter worth $356,000. 10.12% of the stock is owned by institutional investors.

DiaMedica Therapeutics Stock Performance

DMAC stock opened at $6.85 on Friday. The stock has a market cap of $369.42 million, a P/E ratio of -9.51 and a beta of 0.98. The stock's fifty day simple moving average is $6.73 and its two-hundred day simple moving average is $6.61. DiaMedica Therapeutics has a 1-year low of $5.24 and a 1-year high of $10.42.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.01. As a group, analysts forecast that DiaMedica Therapeutics will post -0.84 earnings per share for the current fiscal year.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases with limited therapeutic options. The company's research is centered on therapies intended to address neurological and kidney-related conditions.

DiaMedica's lead product candidate is rinvecalin, also known as DM199, a recombinant form of human tissue kallikrein-1. The company is evaluating rinvecalin as a potential treatment for acute ischemic stroke and kidney diseases, including conditions involving impaired renal function.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.